Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness Wire • Tuesday
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerBusiness Wire • Monday
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesBusiness Wire • 10/20/26
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Zacks Investment Research • 10/19/26
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to SurgeZacks Investment Research • 10/15/26
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeZacks Investment Research • 10/02/26
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian CancerZacks Investment Research • 09/21/26
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)Business Wire • 09/18/26
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?Zacks Investment Research • 09/16/26
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-TermZacks Investment Research • 08/05/26
Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows ItSeeking Alpha • 07/31/26
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 07/29/26
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate UpdateBusiness Wire • 07/29/26